Low-molecular-weight peptidyl aldehyde inhibitors of HIV protease that reach in vivo plasma concentrations after oral administration sUbstantial~hexcess of the antiviral IC eo are described. We alsaiieport efforts to improve the potency and stability of these compounds that culminated in a series of peptidyl trifluoromethyl ketones with increased potency but decreased bioavailability.
Introduction
Extensive research over the last 5 years has demonstrated that the virally encoded aspartic acid protease of the human immunodeficiency virus (HIV PR)is required for the production of infectious virus particles (Kohl et al., 1988; Peng et et., 1989) . This essential role in viral replication, together with the abundance of structural information currently available from mechanistic and crystallographic studies, has established HIV PR as a prime target for potential AIDS therapy. The discovery of therapeutically useful HIV protease inhibitors involves a number of challenges, however, not least of which are the peptidyl nature of most aspartyl protease inhibitors reported to date (reviewed in Huff, 1991 and Debouck, 1992) and the absence of a reliable efficacy model for HIV disease in animals (McClune, 1991; Mosier et a/., 1991; Agy et al., 1992) . Our strategy was to require that a lead HIV PR inhibitor demonstrate in vivo safety and sustained plasma levels in animals, following oral administration, that are significant multiples of the concentration required to inhibit viral replication by 90% (antiviral ICgo).
Of the many classes of HIV protease inhibitors reported, potent compounds tend to be large and predominantly peptidic in nature. It has been difficult to combine potency with adequate oral bioavailability: problems with oral availability with these types of structure have been attributed to poor absorption, rapid clearance, metabolic instability or some combination of these factors; similar difficulties were encountered in identifying orally available inhibitors of renin (Greenlee and Siegel, 1991) . Such problems in the development of renin inhibitors have been addressed, with limited success, by reducing molecular weight, decreasing the number of amide bonds, adding water-solubilizing groups, optimizing 10gP, and blocking terminal amino and carboxyl groups to avoid enzymatic degradation (Rosenberg et al., 1991) . During the course of this work, several laboratories reported progress in identifying inhibitors of HIV with improved pharmacokinetic properties: these developments are reviewed in Wlodawer and Erickson (1993) and Kempf et al. (1993) ;see also Lam et a/. (1994) .We report here the synthesis and pharmacological characterization of low-molecular-weight peptidyl aldehydes which represent one of the few published examples of HIV protease inhibitors that develop in vivo plasma concentrations that substantially exceed the anti-virallCgo• We also describe efforts to improve the potency and stability of these compounds.
Results
A leadseries that we identified early in our programme involved the coupling of aldehydes 1 to diols 2 (Jadhav et al., 1991; Jadhav and Woerner, 1992 ) mediated by TRIS[tetrahydrofuranyl]vanadium trichloride in the presence of a zinc-copper couple (Freudenberger et al., 1989) (Fig. 1) . The product compounds, exemplified by 2, show excellent potency in vitro but have poor oral bioavailability (F% < 5.0%) in experimental animals. Many similar C 2 symmetrical diols have been reported in the literature; the most recent studies suggest that introduction of asymmetry into the structure can improve oral bioavailability (Kempf et a/., 1990 (Kempf et a/., , 1993 . As one of our goals was to reduce molecular weight, and since aldehydes have been reported as moderate inhibitors of aspartyl proteases including HIV PR (Rich, 1986; Stella et al., 1991; Sarubbi et al., 1993) , precursor aldehydes representing 'half-molecules' of potent C 2 symmetrical diols were also evaluated as protease inhibitors (Fig. 1) .
Aldehyde 1A showed only moderate affinity for HIV PR 1 (1A: R = 2-Propyl) aK; values were measured using a Chromogenic peptide substrate described by Cheng et al. (1990a) , using 5-25nM recombinant HIV protease as described in Materials and Experimental procedures. bThe ability to inhibit virus replication was measured via yield reduction essentially as described by Smallheer et al. (1993) . The concentration of compound that reduced by 90% the yield of infectious virus particles was designated lhe ICgo. "The concentration of compound that produced a 50% reduction in the number of viable cells as determined by metabolism of tetrazolium dye was designated the TC so. dThe ability of compound to inhibit the HIV protease-mediated processing of the gag polyprotein in chronically infected Molt-4 cells was assessed by radioimmunoprecipitation as described in Materials and Experimental procedures.°B ioavailability parameters were determined as described in Materials and Experimental procedures. As racemization to the d,l mixture of aldehydes occurred immediately upon exposure to aqueous plasma, the F% was calculated to be over 50% when the d and I forms of the aldehyde parent were considered. The terminal elimination half-life for d + I aldehyde was 15 min, that for the carboxylic acid was 24 min and that for CBZ-valine was 3.2 h (see Fig. 3 ).
(K; = 4J.LM, Table 1 ); however, the translation of cell-free enzyme inhibition into whole-cell reduction of viral yield appeared extremely favourable, so oral availability was measured to determine if this series would be worth optimizing. These data are summarized in Table 1 , with corresponding values for diol 2A included for reference. Plasmalevelsgreater than 1O-foldhigherthan the concentration required to inhibit viral replication by 90% were observed following oral doses of 100mg kg-1, and were sustained over at least 90min despite a short terminal phase half-life (Table 1) . This suggests a prolonged absorption phase for the aldehyde. That the antiviral activity was due to inhibition of HIV protease activity in the infected cells was demonstrated by the quantitatively similar decreases in viral polyprotein processing in chronically infected cells and progeny virus in the presence of the compound, as measured by radioimmunoprecipitation. Unfortunately (but not unexpectedly), the short half-life and the tendency of the aldehyde to undergo racemization on exposure to aqueous acid or base obviated any hope of clinical utility. Further analogue synthesis, including the addition of amino acid residues to occupy additional subsites in the enzyme active site, yielded more potent aldehydes; however, an increase in cytotoxicity occurred as potency against HIV protease increased. For example, the addition of a penultimate phenylalanine to form the tetrapeptide analogue CBZ-F-V-F-CHO increased binding by 1O-foldand cytotoxicity by 3D-fold (data not shown). These changes also diverged from our target of a low-molecular-weight series of compounds.
We next determined the factors responsible for in vivo instability in order to allow the design of analogues that could overcome such problems. It was observed that the aldehyde was rapidly converted to the acid followed by cleavage to protected valine 3 after oral administration to the rat (Fig. 2) . The carboxylic acid analogue showed little potency against HIV protease in vitro (~> 50 t-LM; see Fig.  3 and Table 2 ).
These results suggested that aldehyde variants that combine enhanced chemical and metabolic stability with increased potency might provide clinically useful agents. From the inactivity of the corresponding carboxylic acid, it was assumed that a significant portion of the affinity arose from either the H-bond-accepting properties of the aldehyde oxygen, the electrophilic nature of the aldehyde Orally available inhibitors of HIV protease 259 (Sarubbi et al., 1993) . The aldehyde moiety was altered to distinguish between these possibilities, and the enzyme affinity measured ( Table 2) . The increased activity of the trifluoromethyl ketone was encouraging, and supported the notion of an electrophilic carbon or a geminal diol being necessary for binding. Trifluoromethyl ketones are effective cleavage-site isosteres for serine proteases (Imperiali and Abeles, 1986; Peet et el., 1990) , and have been reported as inhibitors of the aspartyl protease renin (Patel et aI., 1993) .
Compound 12 was subjected to the same battery of tests as described earlier, with the results noted inTable 3.
Substitution of the labile aldehyde moiety with the more stable trifluoroketone resulted in increased enzyme inhibition and in vivo half-life, but decreased potency of inhibition of viral replication. A similar observation of loss of whole-cell activity on changing from diols to fluoroketones was reported for a series of higher molecular weight HIV protease inhibitors (Sham et aI., 1991) . More importantly, despite an increase in plasma half-life, oral availability was lower than was observed with the aldehyde, Fig. 3 . Basic structure of compounds used in Table 2 , where Y is the substituted aldehyde function. 
Discussion
Materials and Experimental procedures: chemistry "Parameters were assessed as described in the legend to Table 1 and in Materials and Experimental procedures. 6.76 g (64%) white crystals with properties consistent with alcohol 4: melting point: 159-160°C; NMR (300MHz, DMSO-d6; mixture of isomers; major isomer): 7.6-7.9 (m, 2H, NH); 7.1-7.3 (M, 5H, aromatic); 4.75 (dd, 1H, valine a-CH, OH); 3.2-3.4 (m, 2H, CH 20H); 2.6-2.9 (m, 2H, phenylalaninol [3-CH 2 ) ; 1.85 (3H, acetyl); 0.8 (6H, dd, valine methyls); MS (CI)measured: 385.212 (M + H); calculated 385.213 (M + H).
(2) A nitrogen-filled, oven-dried 500ml flask was charged with 35 ml CH 2CI2 and 2.90g oxalyl chloride (25.25mmol) under N 2 and cooled to -60°C. Dry dimethylsulfoxide (2.42g, 33.6mmol) in 40 rnl CH 2Cb was added over 10 min. The mixture was stirred for 15min at -60°C, and alcohol 4 (6.00g, 16.8mmol) was added in 100ml THF/CH 2CI2 (1:1 v/v). After stirring for 25min at -60°C, triethylamine (6.8g, 67.2mmol) was added in 20ml CH 2CI2 • The reaction was stirred for 30min at -60°C and quenched with 20% aqueous KHS0 4 (150ml) at -60°C. A white solid formed as water froze. 180 ml hexane was added and warmed to room temperature. The aqueous layer was separated and washed with ether. The organic layers were combined, filtered to remove the white solid (presumably unreacted, insoluble starting alcohol), washed sequentially with saturated aqueous HaHC0 3 , water and brine, and dried over MgS0 4. This yielded 5.12 g white solid. An analytically pure sample can be obtained by recrystallization from EtOAc/hexane, but the aldehyde is very readily epimerized at the a-carbon, and a small amount of the S,R isomer is generally observed in large-scale preparation or other manipulation.
NMR ( 
Synthesis oftrifluoromethyl ketone 12 (N2-[(phenylmethoxy)-car-bonyl}-N-[3,3,3-trifluoro-2-hydroxy-1-(phenylmethylj-propyl-Lvalinamide.
(1) Preparation of trifluoromethyl alcohol 10 (N2-[(phenylmethoxy)-carbonyl]-N-[3,3,3-trifluoro-2-hydroxy-1-(phenylmethyl)-propyl-L-valinamide). A mixture of 1.25g (5.70mmol) of 3-amino-4-phenyl-1,1,1-trifluoro-2-butanol, 10 ml of dimethylformam ide (DMF),2.23 g (6.00mmol) of CBZ-L-Valine p-nitrophenyl ester, and 0.92g (6.00mmol) of 1-hydroxybenzotriazole monohydrate was stirred at room temperature for 16h. The mixture was distributed between 100 ml each of EtOAc and water. The EtOAc solution was washed three times with 10% aqueous NaHC0 3 , once with brine, dried (Na2S04),and evaporated to give 3.46 g of crude residue. The residue was chromatographed on silica gel with 60:10:30 toluene:EtOAc:hexane, stepping to 60:20:20 toluene:EtOAc:hexane, and then to 60:40 toluene: EtOAc. This yielded 0.495 g (19%) of white crystalline solid, which was identified as the desired fluoroalcohol 10, CBZ-L-Val-Phe-(CH(OH)CF 3 ) , with the following properties. TLC: Rf 0.51 (silica gel, 60:40 tol-EtOAc). NMR (CDCI (2) Oxidation of the fluoroalcohol to the fluoroketone. A mixture of 2.49g (5.50mmol) of fluoroalcohol (part 1), 100ml of dry, degassed dichloromethane, and 9.34g (2.20mmol) of periodinane (Dess and Martin, 1983) Table 2 Synthesis of aldehydes. (1) N-Carbobenzyloxyalanine (6.63g, 29.7 mmol; Sigma Chemical Company, St Louis, MO) was dissolved in 30ml tetrahydrofuran (THF) in a 100ml oven-dried flask under N 2 and stirred at room temperature while adding 1,1'-carbonyl diimidazole (4.82g, 29.7 mmol; Aldrich Chemical Company, Milwaukee, WI) neat. After stirring the mixture for 30 min, (s)-phenylalanlnol (4.5g, 29.7mmol; Sigma Chemical Company) was added and stirring was continued for 18h. The mixture was poured into a separatory funnel and the flask rinsed with dichloromethane. 100 ml of dichloromethane was added followed by 50ml of saturated aqueous disodium-L-tartaric acid. The funnel was shaken, the aqueous layer was removed, and the organic layer was washed with saturated bicarbonate followed by brine (saturated aqueous sodium chloride) and dried with magnesium sulfate. Filtration and solvent removal yielded a white solid. The solid was recrystallized by dissolving in hot ethyl acetate (EtOAc), filtering, and adding hexane until cloudy. This yielded such that maximum plasma levels exceeding the antiviral ICgo were not achieved even at high compound dosages.
Representative procedures for preparation of compounds in
Although lacking potent antiviral activity or enzyme inhibition, the peptidyl aldehydes reported herein reach extremely high concentrations in plasma after oral administration. Modifications to these molecules that enhanced enzyme potency tended to reduce oral availability, increase cytotoxicity or decrease the antiviral activity. Current efforts are aimed at understanding the molecular bases of these observations, particularly the factors that influence the translation of a potent enzyme inhibitor to a potent antiviral agent, and at applying this understanding to the optimization of other low-molecularweight compounds with significant oral bioavailability (Lam et al., 1994) .
Parameter measured temperature. 200ml of EtOAc, 200ml of water, 8g of sodium bicarbonate, and 10g of sodium thiosulfate were added and mixed for 15min. The mixture was partially evaporated to remove most of the dichloromethane, and the volume was restored by addition of EtOAc. The EtOAc layer was separated, washed (brine), dried (Na2S04), and evaporated to give 3.71 g of crude product. Recrystallization from toluene yielded 2.8~g of the ketone, with the following properties. TLC: Rf 0.41 (silica gel, 60:40 toluene-ethyl acetate). NMR (CDCla): (TMS:) 0.71 (d, 3H, CH a); 0.78 (d, 3H, CH a); 1.92 (m, 1H, valine CH); 2.90 and 3.30 (two rn, 2H, phenylalanine CH 2); 3.91 (m, H, alpha CH); 4.27 (m, H, alpha CH); 5.09 (s, 2H CBZ CH 2); 5.7 (d, 1H, NH); 6.5 (s, IH, NH); 7.1-7.4 (m, 10H, arom.).IR, 1765cm-1 (fluorinated ketone). Mass spectrum: (M + H), calcd: 451.53; found: 451.58.
Compound 6. The anti oxime was prepared from 383 mg (1mmol) aldehyde 1A, 280mg (4mmol) hydroxylamine hydrochloride, and 544mg (4mmol) sodium acetate trihydrate in 90% ethanol. After evaporation, extraction with EtOAc, and re-evaporation, the mixture yielded a residue which was dissolved in a small amount of warm chloroform and allowed to crystallize. Mass spectrum: (M + H)+ calcd for C22H2704 398.2080; found 398.2071. 1H NMR (300MHz, d6 DMSO) : assigned the 'anti' isomer on the basis that the carbaldol$jhe C-H appeared at 6.59 ppm, upfield from that of compoundif (Phllllps, 1958; Lustig, 1961) .
Compound 7. The syn oxime was prepared by chromatography of the residue from the mother liquor from crystallization of the anti oxime 6.
Step gradients of methanol in chloroform were used to elute the syn oxime from silica gel. The residue was crystallized from toluene. Mass spectrum: (M + H)+ calcd for C22H27NOa04 398.2080, found 398.2085. 1H NMR (300MHz, d6 DMSO): assigned the 'syn' isomer on the basis that the carbaldoxime C-H appeared to be buried downfield in the aromatic protons at 7.17-7.40ppm.
Compound 9. The semicarbazone was prepared from 383 mg (1 mmol) aldehyde 1A, 223 mg (2mmol) semicarbazide hydrochloride, and 270mg (2mmol) 
Materials and Experimental procedures: virology

Measurement of inhibition of HIV protease
The chromogenic peptide Ala-Thr-His-Gln-Val-Tyr-Phe(N0 2)-Val-Arg-Lys-Ala was synthesized as described by Cheng et al. (1990b) . Various concentrations of test compounds were incubated together with recombinant HIV-1 protease (Cheng et al., 1990a) in 50mM MES, pH 5.5, 1.0M NaCI, 1 mM EDTA, 1 mM dithiothreitol and 20% glycerol at room temperature. Substrate was added to a final concentration of 232 tJ.M. The concentration of HIV protease was 5-25 nM. The decrease in absorbance at 300nM coincident with cleavage at the Tyr-Phe(N0 2) bond was recorded over a 10 min period at room temperature. Values for~O rally available inhibitors of HIV protease 261 were determined from measurements of per cent activity compared to uninhibited reactions. Measurement of enzyme inhibition over a range of substrate concentrations indicated that aldehyde 1A was a competitive inhibitor of HIV protease (data not shown).
Measurement of gag polyprotein processing in chronically infected cells
Molt-4 cells were infected with HIV-1(RF) and stably infected cultures were established by maintaining the acutely infected cells until the cells surviving the acute infection grew out. The Molt-4/HIV-1 (RF) cells stably produced HIV for 3-6 months before the titre of virus decreased (as determined by radioimmunoprecipitation). Cells were treated with the compound at various concentrations overnight, starved in DMEM lacking cysteine and methionine for 1 h, and labelled with aSS-cysteine and asS_ methionine for 4 h. Labelled cells and cell-free virus were separated by centrifugation, and an aliquot was lysed in buffer containing 1.0% Triton X-100, 50mM TRIS HCI, pH 7.4 and 150 mM NaCI, and immunoprecipitated with a rabbit polyclonal serum raised against purified viral p24. Goat anti-rabbit Ig bound to a microspherical support (Calbiochem, La Jolla, CAl was added and the immune complexes collected by centrifugation. The pelleted complexes were washed 2 times with buffer containing 50mM TRIS HCI, pH 7.4, 150mM NaCI, 1% Triton X-100, 6mM EDTA and 0.1% SDS, boiled in Laemmli SDS PAGE sample buffer, and subjected to SDS PAGE (Laemmli, 1970) . 14C molecular weight markers were used to identify full-length gag polyprotein precursor (55kDa), and mature p24. Radiolabelled bands corresponding to the viral precursors and proteins were quantified with an AMBIS Radioanalytic Scanner (San Diego, CAl. The concentration of compound that resulted in a 90% decrease in the radiolabelled band corresponding to mature p24 was designated the ICgo.
Yield reduction assay
The yield of infectious virus during exposure to the test compounds was determined as described previously (Smallheer et aI., 1993) . Briefly, MT-2 cells were infected with HIV-1(RF) and exposed to graded concentrations of test compound. Following incubation for 3 days at 36°C, cell-free infectious virus was quantified by plaque assay on monolayers of MT-2 cells. The concentration of compound that reduced the yield of infectious virus by 1 log or 90% compared to the untreated controls was designated the ICgo.
Bioavailability and pharmacokinetic parameters
Male rats were dosed with compounds in a formulation of propylene glycol:polyethylene glycol 400 50:50 at 100 mg kg-1 po or 10 mg kg-1 iv. Blood samples were taken up to 8 h after dosing. Compounds were extracted from plasma by solid phase extraction with C18 cartridges (Waters/Millipore, Milford, MA) following denaturation of samples with guanidine hydrochloride (Horecker et al., 1983) . Extracts were chromatographed on reverse-phase Zorbax Protein Plus columns (available from MacMod Analytical Inc., Chadds Ford, PAl developed with acetonitrile (18% to 63% in 0.1% aqueous trifluroacetic acid over 40 min). Absorbance at 220nm was monitored. Plasma concentrations were determined by interpolation from standards extracted in an identical fashion from rat plasma. The maximum plasma concentration (Cmaxl is the observed peak concentration after an oral dose. The plasma elimination half-life is determined by linear regression of the terminal phase of the logarithmic plasma concentration-time curve. The area under the plasma concentration-time curve (AUG)is determined by the linear trapezoidal rule. Oral bioavailability (F%) was determined by the ratio [AUCpc!AUC iv ] , where AUC was normalized for dose.
